Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. The company is headquartered in The Woodlands, Texas and currently employs 8 full-time employees. The company went IPO on 2024-01-29. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. The company is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The firm is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.
최신 재무제표(Form-10K)에 따르면, Autonomix Medical Inc의 총 자산은 $0이며, 순손실입니다.
AMIX의 주요 재무 비율은 무엇인가요?
Autonomix Medical Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Autonomix Medical Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Autonomix Medical Inc 주요 수익원은 Growth Direct Systems, Proprietary Consumables, Laboratory Information Management System Connection Software이며, 최신 수익 발표에서 수익은 18,728,000입니다. 지역별로는 United States이 Autonomix Medical Inc의 주요 시장이며, 수익은 10,639,000입니다.
Autonomix Medical Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Autonomix Medical Inc의 순손실은 $0입니다.